PUBLISHER: TechNavio | PRODUCT CODE: 1502325
PUBLISHER: TechNavio | PRODUCT CODE: 1502325
Technavio has been monitoring the gastroesophageal reflux disease (GERD) market and is forecast to grow by USD 879.8 mn during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. Our report on the gastroesophageal reflux disease (GERD) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population, poor lifestyle patterns, and overuse of medicines and dietary supplements.
Technavio's gastroesophageal reflux disease (GERD) market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 3.06% |
CAGR | 3.2% |
Incremental Value | $879.8mn |
By Route Of Administration
By Type
By Geography
This study identifies the rising prevalence of obesity as one of the prime reasons driving the gastroesophageal reflux disease (GERD) market growth during the next few years. Also, growing e-commerce market and increasing awareness of GERD will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the gastroesophageal reflux disease (GERD) market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastroesophageal reflux disease (GERD) market vendors that include Abbott Laboratories, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, inovapharma.com, Johnson and Johnson Services Inc., Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and The Procter and Gamble Co.. Also, the gastroesophageal reflux disease (GERD) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: